Colossal Foundation Partners With University of Tasmania on Vaccines and Gene Editing to Fight Devil Facial Tumour Disease
A contagious facial cancer has erased roughly 80% of Tasmania's wild devils since it surfaced in the 1990s, and biting, a natural behavior for feeding and mating, spreads it faster than conservation can contain it. The Colossal Foundation, the nonprofit conservation arm of Colossal Biosciences, is now joining the fight. It has partnered with the University of Tasmania to attack Devil facial tumour disease (DFTD) on two fronts.
Colossal Foundation Commits $500,000 to Restore the Bolson Tortoise to the American Southwest
The Colossal Foundation, the 501(c)(3) charitable organization associated with Colossal, the de-extinction company, today announced a $500,000, 5 year commitment to the Turner Endangered Species Fund (TESF) to advance the recovery and rewilding of the Bolson tortoise (Gopherus flavomarginatus), North America’s largest and rarest tortoise species, within its prehistoric range.
Colossal Foundation Announces the Colossal Species Reintroduction Fund; First-Ever Dedicated Accelerator for Rewilding Animals to Native Habitats Globally
The Colossal Foundation, the 501(c)(3) charitable organization of Colossal Biosciences, the de-extinction company, today announced the launch of its Species Reintroduction Fund. In collaboration with conservation non-profit, Re:wild, this first-of-its-kind fund will dedicate at least $250,000 annually to support every phase of reintroduction–including planning, genetic assessment and post-release monitoring for threatened species across terrestrial and aquatic ecosystems worldwide.
